Canadian guidelines on post-NOC changes reflect new policy
This article was originally published in SRA
Executive Summary
Following extensive consultation with stakeholders, Health Canada has finalised a set of guidelines that reflect the authority’s new policy on reporting postapproval changes to drugs, biologics and radiopharmaceuticals1. The guidelines came into effect on 30 September.